INT194533

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 2006
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 8
Disease Relevance 3.86
Pain Relevance 0.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

UOX (Homo sapiens)
Pain Link Frequency Relevance Heat
abdominal pain 7 99.80 Very High Very High Very High
headache 14 98.00 Very High Very High Very High
adenocard 17 34.00 Quite Low
Onset of action 7 20.24 Low Low
fibrosis 7 6.32 Low Low
Inflammation 18 5.00 Very Low Very Low Very Low
Arthritis 18 5.00 Very Low Very Low Very Low
Pain 15 5.00 Very Low Very Low Very Low
Bioavailability 8 5.00 Very Low Very Low Very Low
pruritus 7 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Abdominal Pain 7 99.80 Very High Very High Very High
Adverse Drug Reaction 23 99.20 Very High Very High Very High
Diarrhoea 28 98.72 Very High Very High Very High
Headache 14 98.00 Very High Very High Very High
Vomiting 28 97.32 Very High Very High Very High
Mucositis 7 96.12 Very High Very High Very High
Neutropenia 15 95.48 Very High Very High Very High
Hyperuricemia 225 95.40 Very High Very High Very High
Sepsis 7 94.76 High High
Respiratory Distress 8 94.24 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Even after 5 days of treatment, a consistent accumulation has not been reported. 13 Interaction studies have been performed in vitro where rasburicase does not show interaction with other drugs.
uricase Binding (interaction) of
1) Confidence 0.47 Published 2007 Journal International Journal of Medical Sciences Section Body Doc Link PMC1838823 Disease Relevance 0.17 Pain Relevance 0
Association between rasburicase and allopurinol should be avoided, because the latter may reduce the effect of rasburicase owing to its inhibition of xanthine oxidase and consequent reduced uric acid concentration. 18
uricase Binding (effect) of
2) Confidence 0.36 Published 2007 Journal International Journal of Medical Sciences Section Body Doc Link PMC1838823 Disease Relevance 0.06 Pain Relevance 0
Association between rasburicase and allopurinol should be avoided, because the latter may reduce the effect of rasburicase owing to its inhibition of xanthine oxidase and consequent reduced uric acid concentration. 18
uricase Binding (Association) of
3) Confidence 0.36 Published 2007 Journal International Journal of Medical Sciences Section Body Doc Link PMC1838823 Disease Relevance 0.12 Pain Relevance 0
Association between rasburicase and allopurinol should be avoided, because the latter may reduce the effect of rasburicase owing to its inhibition of xanthine oxidase and consequent reduced uric acid concentration. 18
uricase Binding (owing) of
4) Confidence 0.36 Published 2007 Journal International Journal of Medical Sciences Section Body Doc Link PMC1838823 Disease Relevance 0.06 Pain Relevance 0
PEG uricase has been associated with the following adverse reactions: a local injection site induration, precocious (within few hours) or tardive (8-9 days), the latter associated with generalized urticaria and arthralgia.
PEG uricase Binding (associated) of associated with urticaria, adverse drug reaction and arthralgia
5) Confidence 0.28 Published 2007 Journal International Journal of Medical Sciences Section Body Doc Link PMC1838823 Disease Relevance 2.26 Pain Relevance 0.20
Neither patients treated with non recombinant urate oxidase nor those treated with rasburicase require dialysis. 13,54
urate oxidase Binding (recombinant) of
6) Confidence 0.25 Published 2007 Journal International Journal of Medical Sciences Section Body Doc Link PMC1838823 Disease Relevance 0.58 Pain Relevance 0
In eight subjects ('long-circulating', Figure 3a), pUox was still measurable at three weeks after injection, whereas in five subjects ('early elimination', Figure 3b) pUox could not be detected beyond day 10 after injection.
pUox Binding (measurable) of
7) Confidence 0.24 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526556 Disease Relevance 0 Pain Relevance 0
The first molecule of this kind, synthetized in 1968 and introduced in France since 1975 and in Italy since 1984, was a non-recombinant urate oxidase. 10 It was a natural uricase, obtained from Aspergillus flavus cultures (Uricozyme TM), used to prevent and treat hyperuricemia occurring during chemotherapy. 10
urate oxidase Binding (recombinant) of associated with hyperuricemia
8) Confidence 0.22 Published 2007 Journal International Journal of Medical Sciences Section Body Doc Link PMC1838823 Disease Relevance 0.60 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox